Innovations in rtCGM to Improve Clinical Outcomes in Diabetes

Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Credit Available: Up to 1.5 credit hours available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)
Expiration Date: October 31, 2024
Click Here to Review – CE EXPIREDEducational Objectives
After completing this activity, the participant should be better able to:
- Assess clinical evidence and professional society guidelines for CGM systems in patients with type 1 or type 2 diabetes
- Characterize the impact of rtCGM on clinical measures of diabetes care
- Implement medical and pharmacy benefit design strategies to support appropriate access to rtCGM and develop evidence-based clinical criteria
Expert Faculty

Matthew D. Harman, PharmD, MPH
VP, Clinical Solutions, Employers Health

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy
Cleveland Clinic Endocrinology & Metabolism Institute

Gary A. Puckrein, PhD
President and Chief Executive Officer, National Minority Quality Forum

Drake Reiter, PharmD
Advisor, Pharmacy Product & Trend, Priority Health
Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.